CN106191064A - 一种制备mc4r基因敲除猪的方法 - Google Patents
一种制备mc4r基因敲除猪的方法 Download PDFInfo
- Publication number
- CN106191064A CN106191064A CN201610587597.3A CN201610587597A CN106191064A CN 106191064 A CN106191064 A CN 106191064A CN 201610587597 A CN201610587597 A CN 201610587597A CN 106191064 A CN106191064 A CN 106191064A
- Authority
- CN
- China
- Prior art keywords
- crispr
- sgrna
- mc4r gene
- targeting vector
- mc4r
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101150110867 MC4R gene Proteins 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 20
- 238000003209 gene knockout Methods 0.000 title claims abstract description 14
- 108091033409 CRISPR Proteins 0.000 claims abstract description 56
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 33
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 25
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 14
- 239000012634 fragment Substances 0.000 claims abstract description 10
- 101100129533 Sus scrofa MC4R gene Proteins 0.000 claims abstract description 8
- 238000010374 somatic cell nuclear transfer Methods 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 41
- 230000008685 targeting Effects 0.000 claims description 36
- 239000013598 vector Substances 0.000 claims description 22
- 239000013612 plasmid Substances 0.000 claims description 19
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 claims description 12
- 102100023724 Melanocortin receptor 4 Human genes 0.000 claims description 12
- 210000002950 fibroblast Anatomy 0.000 claims description 10
- 230000009471 action Effects 0.000 claims description 9
- 210000001161 mammalian embryo Anatomy 0.000 claims description 9
- 210000000287 oocyte Anatomy 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 210000003101 oviduct Anatomy 0.000 claims description 5
- 210000002257 embryonic structure Anatomy 0.000 claims description 4
- 238000010449 nuclear transplantation Methods 0.000 claims description 4
- 230000001605 fetal effect Effects 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 claims 1
- 238000013461 design Methods 0.000 abstract description 4
- 238000012239 gene modification Methods 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 230000005017 genetic modification Effects 0.000 abstract description 2
- 235000013617 genetically modified food Nutrition 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 241000282898 Sus scrofa Species 0.000 description 20
- 229940088598 enzyme Drugs 0.000 description 11
- 210000003754 fetus Anatomy 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 101150063416 add gene Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000005782 double-strand break Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 101150038500 cas9 gene Proteins 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
- 101710200814 Melanotropin alpha Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007683 Pediatric Obesity Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000003295 arcuate nucleus Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000010002 chemokinesis Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 108010087236 cobra venom endonuclease Proteins 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 102220095038 rs876660955 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8778—Swine embryos
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及基因工程和遗传修饰领域,具体地说,涉及利用CRISPR/Cas9系统对MC4R基因进行编辑,并通过体细胞核移植技术获得MC4R基因敲除猪。本发明首次针对猪MC4R基因的CDS区的两个位点(MC4R基因CDS区的6133‑6152bp序列和7127‑7146bp序列)设计sgRNA,并借助CRISPR‑Cas9系统对两个位点同时进行切割,实现了MC4R基因的大片段删除,并且获得了大片段删除的敲除猪个体,为研究猪MC4R基因提供了一种切实可行的方法。
Description
技术领域
本发明涉及基因工程和遗传修饰领域,具体地说,涉及利用CRISPR/Cas9系统对MC4R基因进行编辑,并通过体细胞核移植技术获得MC4R基因敲除猪。
背景技术
PVN是食欲调节的一把钥匙,主要表达MC4R。在PVN区,MC4R的活性受弓状核不同神经元分泌的激素调节(如激动剂α-MSH和拮抗剂Agrp等)。MC4R与配体结合后被活化,细胞外的信号传到细胞内,激活腺苷酸环化酶,使细胞内cAMP浓度增高。最终激活cAMP应答元件(cAMPresponseelement,CRE)调控的基因转录,从而调节细胞的物质代谢和基因表达。MC4R除参与经典的信号调节通路外,它还调节MAPK信号通路中某些信号因子的活性,发挥减少体重的功能。
MC4R可以作为大动物育种的一个候选基因。该基因的突变与体重及脂肪性状的呈现显著的相关性。如猪MC4R基因高度保守区内发生一个错义突变Asp298Asn,该位点多态性与猪的许多经济性状显著相关:MC4R基因型为298Asp时,猪表现为背膘厚减少、增长速度变慢、采食量降低,MC4R基因型突变为298Asn时,猪表现为背膘厚增多、增长速度加快、采食量提高等相关性状。
MC4R基因突变是最常见的单基因肥胖病因,占早期开始的严重儿童期肥胖的4%。
因而MC4R基因对于农业上大动物的育种改良,以及医学上的治疗早发性肥胖具有重要的意义。
因而通过制作基因敲除猪,在此模型的基础上阐明MC4R在猪脂肪发育中信号通路的作用,具有重要的意义。
CRISPR/Cas9是一种存在于细菌和古生菌中的适应性免疫系统。利用人工合成的sgRNA序列与基因组DNA的碱基互补配对,Cas9核酸内切酶可以实现基因组的定点切割,从而产生DNA的双链断裂。DNA双链断裂可以通过两种方式进行修复:其一是采取非同源末端连接修复方式(NHEJ),这种方式会在双链断裂处产生随机类型的插入/缺失修复,可能会造成基因的移码突变,造成基因功能缺失。另一种修复方式是在以单链寡核苷酸或者双链Donor质粒载体为模板的指导下,通过同源重组(HR)的方式实现预期的精准修复。
发明内容
为了解决现有技术中存在的问题,本发明的目的是提供一种制备MC4R基因敲除猪的方法。
为了实现本发明目的,本发明首先提供特异性靶向MC4R基因的sgRNA,其靶向MC4R基因CDS区6133-6152bp序列或7127-7146bp序列。
进一步地,当所述sgRNA靶向MC4R基因CDS区6133-6152bp序列时,其核苷酸序列为5’-ttctggaaccgcagcaccta-3’。
当所述sgRNA靶向MC4R基因CDS区7127-7146bp序列时,其核苷酸序列为5’-gactttctccttacacagtc-3’。
其次,本发明还提供了含有前述sgRNA的CRISPR/Cas9打靶载体。作为优选,其为连接有sgRNA的px-330质粒,所述pX330质粒购于Addgene公司。
所述CRISPR/Cas9打靶载体,是通过以下方法制备得到的:以合成引物的方式,合成sgRNA及其互补的寡核苷酸序列。将寡核酸序列进行退火操作,步骤为在94℃,5min;37℃,10min;冰上,5min。用限制性内切酶BbsⅠ酶切pX330质粒,切胶回收载体骨架,利用T4DNA连接酶与退火后的寡核苷酸产物进行连接。
进一步地,本发明还提供了一种制备MC4R基因敲除细胞的方法,将含有靶向MC4R基因CDS区6133-6152bp序列的sgRNA的CRISPR/Cas9打靶载体,与含有靶向MC4R基因CDS区7127-7146bp序列的sgRNA的CRISPR/Cas9打靶载体共转染细胞,从而敲除细胞的MC4R基因。
与此同时,本发明还提供了一种制备MC4R基因敲除猪的方法,即同时利用靶向MC4R基因CDS区6133-6152bp序列的CRISPR/Cas9打靶载体与靶向MC4R基因CDS区7127-7146bp序列的CRISPR/Cas9打靶载体,对MC4R基因实现敲除。
具体而言,所述方法包括如下步骤:
(1)将含有靶向MC4R基因CDS区6133-6152bp序列的sgRNA的CRISPR/Cas9打靶载体、含有靶向MC4R基因CDS区7127-7146bp序列的sgRNA的CRISPR/Cas9打靶载体、与PL452-Neo质粒分别进行酶切,得到线性化片段;所述pl452-Neo质粒购于Addgene公司;
(2)将步骤(1)得到的线性化片段共转染猪的胎儿成纤维细胞,通过G418(遗传霉素)筛选具有抗性的单细胞克隆;
(3)选取状态良好的阳性单细胞克隆作为核移植的供体细胞,卵母细胞作为核移植的受体细胞,利用体细胞核移植技术构建克隆胚胎,将优质的克隆胚胎移植到代孕母猪的输卵管内,经过全期发育获得MC4R基因敲除猪。
其中,CRISPR/Cas9打靶载体pX330(包括靶向MC4R基因CDS区不同序列的两种CRISPR/Cas9打靶载体pX330)与PL452-Neo基因进行共转猪的胎儿成纤维细胞的方法为:pX330质粒的总量为4μg(两种pX330各2μg),PL452-Neo基因线性载体与pX330质粒按照摩尔比1:3混合,利用lonza核电转仪及成纤维细胞电转试剂盒进行转染。
进一步地,本发明还提供了前述sgRNA或前述CRISPR/Cas9打靶载体在CRISPR-Cas9特异性敲除猪MC4R基因中的应用。
本发明的有益效果在于:
本发明首次针对猪MC4R基因的CDS区的两个位点设计的sgRNA,并借助CRISPR-Cas9系统对两个位点同时进行切割,实现了MC4R基因的大片段删除,并且获得了大片段删除的敲除猪个体,这种制备MC4R基因敲除猪的方法在国内外之前是没有报道的。为研究猪MC4R基因提供了一种切实可行的方法。
附图说明
图1为本发明实施例1中针对MC4R基因设计的靶向序列位置。
图2为本发明实施例7中对单克隆细胞进行测序后,序列比对的结果。
图3为本发明实施例9中使用PCR方法鉴定新生猪的突变类型;其中,1号为820,2号为11502,3号为11501,4号为11503,5号为死胎,WT为野生型。
具体实施方式
下面将结合实施例对本发明的优选实施方式进行详细说明。需要理解的是以下实施例的给出仅是为了起到说明的目的,并不是用于对本发明的范围进行限制。本领域的技术人员在不背离本发明的宗旨和精神的情况下,可以对本发明进行各种修改和替换。
下述实施例中所使用的实验方法如无特殊说明,均为常规方法。
下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
其中:
pX330载体,pl452-Neo质粒购于Addgene公司;
T4DNA连接酶、Q5超保真酶、BbsⅠ及T7EN1购于NEB公司;
引物合成由上海生工完成;
测序由美吉生物公司合成。
质粒去内毒素提取试剂盒及基因组提取试剂盒购于QIAGEN公司。
胶回收试剂盒购于GENSTAR公司。
酶切、连接、切胶回收、转化、PCR扩增等常规实验操作步骤详见《分子克隆(第三版)》。
实施例1、CRSIPR/Cas9打靶载体cas-1-3、cas-3-3的构建
根据CRISPR/Cas9的作用原理,在猪MC4R基因的CDS区设计sgRNA序列,如图1所示。
选取cas9靶点1-3:
sgRNA序列为5’-ttctggaaccgcagcaccta-3’,根据碱基互补配对的原则,其反向互补序列为5’-taggtgctgcggttccagaa-3’;
选取cas9靶点3-3:
sgRNA序列为5’-gactttctccttacacagtc-3’,根据碱基互补配对的原则,其反向互补序列为5’-gactgtgtaaggagaaagtc-3。
pX330载体骨架需要使用BbsⅠ进行酶切,所以需要在sgRNA序列上补出BbsⅠ酶切位点的粘性末端,以利于其连入pX330载体骨架。加入BbsⅠ粘性末端的sgRNA序列及其互补序列。
a.将设计好的加入BbsⅠ酶切位点粘性末端的sgRNA及其互补序列以合成引物的方式进行合成。将合成的寡核苷酸进行退火操作,使其形成带有粘性末端的DNA双链。退火程序如下:94℃,5min;37℃,10min;冰上,5min。
b.pX330载体骨架使用BbsⅠ酶切,37℃水浴4h。然后进行琼脂糖凝胶电泳,并切胶回收目的条带。
c.载体骨架与sgRNA序列连接。将回收的载体骨架与sgRNA序列退火产物于16℃连接仪进行连接过夜。将连接产物转化DH5α感受态细胞,37℃培养箱培养,待其长出单克隆后,挑取单克隆划线,并进行测序鉴定阳性单克隆。测序引物为F:5'-GAGGGCCTATTTCCCATGAT-3';R:5'-GGAAAGTCCCTATTGGCGTTA-3'。构建好的质粒(打靶载体)命名为cas-1-3、cas-3-3。
实施例2、阳性菌落的大量培养
a.挑取测序正确的阳性单克隆菌落,将其加入2-5ml氨苄抗性的LB培养基中,于摇床中37℃,300rpm剧烈摇动8h。
b.将初始培养的菌液以1/500-1/1000的稀释比例加入到100ml氨苄抗性的LB培养基中,于摇床中37℃,300rpm剧烈摇动12h-16h。
实施例3、cas-1-3、cas-3-3质粒的去内毒提取
参见QIAGEN公司的EndoFree Plasmid Maxi Kit说明书。将提取好的质粒测浓度后分装、冻存,用于后续的猪胎儿成纤维细胞的转染。
实施例4、PL452-Neo质粒的酶切
使用NEB公司的限制性内切酶NotⅠ和NheⅠ对PL452-Neo质粒酶切,37℃水浴4h。使用Genstar的胶回收试剂盒回收,测浓度后分装,冻于-20℃冰箱备用。
实施例5、猪胎儿成纤维细胞的建系
a.将妊娠30天的农大小香猪麻醉,从其子宫内无菌取出胎儿,用含双抗的PBS清洗胎儿后,置于超净工作台中,用眼科剪去除胎儿的头部、四肢、内脏及软骨组织,用PBS冲洗干净;
b.在细胞培养皿内用眼科剪将剩余组织剪碎成约1mm3小块;
c.加入适量的FBS,保持组织不至于过分干燥。将剪碎的组织块转移到1个T75细胞培养瓶中,将组织块均匀铺开;
d.加入5mL细胞培养基,将铺有组织块的一面向上,不被培养基浸没,于37℃,5%CO2培养箱中培养3~5h后,将T75翻转,使组织块被培养基浸没;
e.培养3天左右,观察到组织块周围有大量细胞爬出,待细胞生长至约90%汇合度时,对细胞进行消化并冻存备用。
实施例6、猪胎儿成纤维细胞的转染和中靶单细胞克隆的筛选:
a.将一个六孔板孔中,已达到80-90%汇合的猪胎儿成纤维细胞,进行消化、离心,获得数量约2×105-2×106的猪胎儿成纤维细胞。
b.将质粒pX330-1-3、pX330-3-3及PL452-Neo基因线性化片段加入Lonza转染试剂中,混匀。
c.使用加入质粒的转染试剂重悬细胞,并将细胞悬液加入到电击杯中,T-016程序电击细胞。
d.电击完成后,立即将细胞吸出,加3ml含10%血清的DMEM到六孔板的一个孔中。
e.37℃,5%CO2培养箱培养48h后,细胞达到80%-90%汇合,将细胞消化下来,稀释至20-30个10cm细胞培养皿中。
f.24-48h后,待10cm皿中的细胞贴壁、且状态良好,加入400-600μg/ml的G418,每隔一天补加一次G418,加药量根据细胞状态及汇合度灵活掌控,总加药量不能超过1000μg/ml。G418筛选10-14天,可见单克隆长出。
g.单克隆的挑取及扩大培养。在显微镜下,使用记号笔将状态良好的单克隆用圆圈圈出。弃掉10cm培养皿中的培养基,PBS清洗一次,将克隆环蘸取明胶,用克隆环将细胞单克隆圈住,加入10-30μl0.1%的胰蛋白酶,37℃消化1min。在显微镜下观察,细胞变圆、游离,加入含20%FBS的DMEM终止消化,将细胞吸出加入24孔板中。48-72h后,24孔板中细胞汇合至80-90%时,将细胞传至12孔板中。待12孔板中细胞达到80%-90%汇合时,对细胞进行冻存。
实施例7、中靶阳性单细胞克隆的鉴定
由于Cas9的切割造成双链断裂,NHEJ的修复方式会随机产生插入/缺失突变,因此我们需要以打靶单克隆的基因组为模板,PCR扩增打靶位点所在区域,对其区域进行测序,检测其碱基的插入/缺失突变的情况。
提取48个单克隆的基因组DNA,以其为模板进行PCR扩增,PCR扩增引物为,PCR产物大小为1427bp。以野生型细胞的基因组作为阴性对照。PCR程序如下:98℃,30s;98℃,10s;56℃,30s;72℃,1min;72℃,2min。35个循环。缺失或者插入大片段的细胞单克隆,可以使用琼脂糖凝胶电泳进行初步判定。将PCR产物连接peasy-simple blunt载体进行测序,序列比对情况如图2所示。
实施例8、MC4R基因敲除猪的制备
a.以实施例7获得的阳性猪胎儿成纤维细胞为核移植供体细胞。培养胎儿成纤维细胞至100%汇合1-2天,去除培养皿内培养基,加入PBS洗涤1次,然后用0.1%胰蛋白酶消化约2min,待细胞变圆后立即后用含血清的细胞培养液终止消化,1000rpm离心5min,弃上清,用操作液T2重悬离心沉淀的细胞,冰浴放置备用。
b.以体外成熟的卵母细胞为核移植受体卵质。从母猪卵巢中采集卵丘卵母细胞复合体,经过体外成熟并用透明质酸酶脱去卵丘细胞,而后在体式显微镜下挑选排出第一极体、形态正常、胞质均匀的成熟卵母细胞备用。
c.在显微操作仪下,将核移植供体细胞移入去核的成熟卵母细胞中。经过电融合及化学激活,诱导细胞与卵子融合并同时激活卵母细胞。构建成重组胚胎,融合胚放入低氧培养环境下(低氧培养箱或充入低氧混合配气封袋密闭培养)培养。采用微滴或四孔板培养,气相条件为含7%O2、88%N2、和5%CO2的混合气体,培养温度为39℃,湿度为100%。体外发育至1-4细胞期后观察卵裂情况及发育状态,并用于胚胎移植。
d.挑选形态正常、发育优良的克隆胚胎用手术法移植入胚胎同期的母猪内。移植步骤为舒泰常规麻醉,将母猪保定在手术架上面,尽量避开血管,在腹中线处切口,露出卵巢,输卵管及子宫,使用胚胎移植管吸取胚胎,然后沿输卵管伞部进入将克隆胚胎释放到输卵管壶腹部、峡部结合处。胚胎移植后给代孕母猪注射消炎针,30天后进行B超检测妊娠情况。
实施例9、MC4R基因敲除猪的DNA水平检测
使用新生公猪820#、11501#、11502#、11503#的耳组织提取基因组DNA,以其为模板对MC4R基因进行PCR扩增。PCR扩增引物F:5'-GATGCTAATCAGAGCCCTAC-3';R:5'-TCCATTGTGCCTATAACCTG-3'。使用该引物对野生型猪基因组DNA进行扩增的PCR产物大小应为1427bp。若新生猪为基因敲除猪,则PCR产物大小约为420bp。结果表明11501#为部分缺失。其他样送测序比对结果表明820#及11502#发生移码突变,翻译提前终止。
虽然,上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (10)
1.特异性靶向MC4R基因的sgRNA,其特征在于,其靶向MC4R基因CDS区的6133-6152bp序列或7127-7146bp序列。
2.根据权利要求1所述的的sgRNA,其特征在于,其核苷酸序列为5’-ttctggaaccgcagcaccta-3’。
3.根据权利要求1所述的的sgRNA,其特征在于,其核苷酸序列为5’-gactttctccttacacagtc-3’。
4.含有权利要求2或权利要求3所述的sgRNA的CRISPR/Cas9打靶载体。
5.根据权利要求4所述的CRISPR/Cas9打靶载体,其特征在于,其为连接有sgRNA的px-330质粒。
6.一种制备MC4R基因敲除细胞的方法,其特征在于,将含有权利要求2所述sgRNA的CRISPR/Cas9打靶载体,与含有权利要求3所述sgRNA的CRISPR/Cas9打靶载体共转染细胞,从而敲除细胞的MC4R基因。
7.一种制备MC4R基因敲除猪的方法,其特征在于,同时利用靶向MC4R基因CDS区6133-6152bp序列的CRISPR/Cas9打靶载体与靶向MC4R基因CDS区7127-7146bp序列的CRISPR/Cas9打靶载体,对MC4R基因实现敲除。
8.根据权利要求7所述的方法,其特征在于,包括如下步骤:
(1)将含有权利要求2所述sgRNA的CRISPR/Cas9打靶载体、含有权利要求3所述sgRNA的CRISPR/Cas9打靶载体、与PL452-Neo分别进行酶切,得到线性化片段;
(2)将步骤(1)得到的线性化片段共转染猪的胎儿成纤维细胞,通过G418筛选具有抗性的单细胞克隆;
(3)选取状态良好的阳性单细胞克隆作为核移植的供体细胞,卵母细胞作为核移植的受体细胞,利用体细胞核移植技术构建克隆胚胎,将优质的克隆胚胎移植到代孕母猪的输卵管内,经过全期发育获得MC4R基因敲除猪。
9.根据权利要求7或8所述的方法,其特征在于,所述CRISPR/Cas9打靶载体为连接有sgRNA的px-330质粒。
10.权利要求1~3任一项所述的sgRNA或权利要求4所述的CRISPR/Cas9打靶载体在CRISPR-Cas9特异性敲除猪MC4R基因中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610587597.3A CN106191064B (zh) | 2016-07-22 | 2016-07-22 | 一种制备mc4r基因敲除猪的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610587597.3A CN106191064B (zh) | 2016-07-22 | 2016-07-22 | 一种制备mc4r基因敲除猪的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106191064A true CN106191064A (zh) | 2016-12-07 |
CN106191064B CN106191064B (zh) | 2019-06-07 |
Family
ID=57491808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610587597.3A Expired - Fee Related CN106191064B (zh) | 2016-07-22 | 2016-07-22 | 一种制备mc4r基因敲除猪的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106191064B (zh) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107099533A (zh) * | 2017-06-23 | 2017-08-29 | 东北农业大学 | 一种特异靶向猪IGFBP3基因的sgRNA导向序列及应用 |
CN107119053A (zh) * | 2017-06-23 | 2017-09-01 | 东北农业大学 | 一种特异靶向猪MC4R基因的sgRNA导向序列及其应用 |
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
CN109055434A (zh) * | 2018-07-05 | 2018-12-21 | 中山大学 | 一种利用CRISPRCas9技术纠正猪KIT基因结构突变的方法 |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
CN112608941A (zh) * | 2020-12-18 | 2021-04-06 | 南京启真基因工程有限公司 | 用于构建mc4r基因突变的肥胖症猪核移植供体细胞的crispr系统及其应用 |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
CN113491255A (zh) * | 2021-06-16 | 2021-10-12 | 温州大学 | 一种肥胖性ii型糖尿病斑马鱼模型的构建方法及应用 |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012129198A1 (en) * | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
CN105463027A (zh) * | 2015-12-17 | 2016-04-06 | 中国农业大学 | 一种高肌肉量及肥厚型心肌病模型克隆猪的制备方法 |
-
2016
- 2016-07-22 CN CN201610587597.3A patent/CN106191064B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012129198A1 (en) * | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
CN105463027A (zh) * | 2015-12-17 | 2016-04-06 | 中国农业大学 | 一种高肌肉量及肥厚型心肌病模型克隆猪的制备方法 |
Non-Patent Citations (4)
Title |
---|
LI DL等: "《Heritable gene targeting in the mouse and rat using a CRISPR-Cas system》", 《NATURE BIOTECHNOLOGY》 * |
MEIDTNER K.等: "登录号:EU169096.1", 《GENBANK》 * |
YANG RUN-JUN等: "《Influence of silencing the MC4R gene by lentivirus-mediated RNA interference in bovine fibroblast cells》", 《AFRICAN JOURNAL OF BIOTECHNOLOGY》 * |
谢胜松等: "《CRISPR/Cas9系统中sgRNA设计与脱靶效应评估》", 《遗传》 * |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US12006520B2 (en) | 2011-07-22 | 2024-06-11 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
US10954548B2 (en) | 2013-08-09 | 2021-03-23 | President And Fellows Of Harvard College | Nuclease profiling system |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US10912833B2 (en) | 2013-09-06 | 2021-02-09 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US11124782B2 (en) | 2013-12-12 | 2021-09-21 | President And Fellows Of Harvard College | Cas variants for gene editing |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11999947B2 (en) | 2016-08-03 | 2024-06-04 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US12084663B2 (en) | 2016-08-24 | 2024-09-10 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
CN107119053A (zh) * | 2017-06-23 | 2017-09-01 | 东北农业大学 | 一种特异靶向猪MC4R基因的sgRNA导向序列及其应用 |
CN107099533A (zh) * | 2017-06-23 | 2017-08-29 | 东北农业大学 | 一种特异靶向猪IGFBP3基因的sgRNA导向序列及应用 |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
CN109055434B (zh) * | 2018-07-05 | 2022-04-29 | 中山大学 | 一种利用CRISPRCas9技术纠正猪KIT基因结构突变的方法 |
CN109055434A (zh) * | 2018-07-05 | 2018-12-21 | 中山大学 | 一种利用CRISPRCas9技术纠正猪KIT基因结构突变的方法 |
US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
US12031126B2 (en) | 2020-05-08 | 2024-07-09 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
CN112608941B (zh) * | 2020-12-18 | 2023-03-21 | 南京启真基因工程有限公司 | 用于构建mc4r基因突变的肥胖症猪核移植供体细胞的crispr系统及其应用 |
CN112608941A (zh) * | 2020-12-18 | 2021-04-06 | 南京启真基因工程有限公司 | 用于构建mc4r基因突变的肥胖症猪核移植供体细胞的crispr系统及其应用 |
CN113491255A (zh) * | 2021-06-16 | 2021-10-12 | 温州大学 | 一种肥胖性ii型糖尿病斑马鱼模型的构建方法及应用 |
CN113491255B (zh) * | 2021-06-16 | 2022-07-15 | 温州大学 | 一种肥胖性ii型糖尿病斑马鱼模型的构建方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106191064B (zh) | 2019-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106191064A (zh) | 一种制备mc4r基因敲除猪的方法 | |
CN105821049B (zh) | 一种Fbxo40基因敲除猪的制备方法 | |
CN105087620B (zh) | 一种过表达猪共刺激受体4‑1bb载体及其应用 | |
CN108949824A (zh) | 基于HMEJ的方法介导Ipr1定点插入获取转基因牛胎儿成纤维细胞的方法 | |
CN107937345B (zh) | 一种制备同时敲除cd163基因和cd13基因的猪成纤维细胞的方法 | |
CN108285906A (zh) | 一种定点整合外源dna转基因猪的构建方法 | |
CN113957069B (zh) | 用于pAPN基因第736位和第738位氨基酸同时修饰的组合物及其应用 | |
CN103725710B (zh) | 一种可自我删除游离载体及其应用 | |
CN107893088A (zh) | 一种制备cd13基因敲除的猪成纤维细胞和基因编辑猪的方法 | |
CN107354170A (zh) | 一种基因敲除载体以及制备cd163基因敲除猪成纤维细胞的方法 | |
CN109112159A (zh) | 基于Cas9介导的定点整合FABP4基因和MSTN基因点突变打靶载体及重组细胞 | |
CN113957093B (zh) | 用于pAPN基因定点修饰的系统及其应用 | |
CN104293833B (zh) | 一种基于TALEN介导的Sp110巨噬细胞特异打靶载体及重组细胞 | |
CN109628494A (zh) | 冠状病毒抗性克隆猪及其制备方法 | |
CN113604504A (zh) | 用于pAPN基因16外显子定点修饰的组合物及其应用 | |
CN103993027B (zh) | 一种转基因猪筛选标记基因敲除的方法 | |
CN104059877A (zh) | 一种“仿比利时蓝牛”mstn基因型的基因编辑猪的制备方法 | |
CN116445454B (zh) | 一种用于培育抗tgev感染的猪品种的成套系统及其应用 | |
CN113403337A (zh) | 一种载体系统、制备猪成纤维细胞和基因编辑猪的方法 | |
CN116790604B (zh) | 一种sgRNA、CRISPR/Cas9载体及其构建方法和用途 | |
CN107988257B (zh) | 基于供体细胞dna甲基化水平的修饰提高山羊克隆效率的载体、细胞及方法 | |
CN109679998A (zh) | 一种定点突变MSTN并同时定点整合PPARγ的载体 | |
CN106591364B (zh) | 一种获取转基因牛胎儿成纤维细胞的方法 | |
CN115948465A (zh) | 猪hat1基因修饰系统及应用 | |
CN113604502A (zh) | pAPN基因第16外显子的基因编辑系统及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190607 Termination date: 20200722 |
|
CF01 | Termination of patent right due to non-payment of annual fee |